Skip to content

The study comparing effects of inhalational milrinone and inhalational levosimendan in children with birth defects of heart with left side to right sided blood movement and hypertension in pulmonary artery undergoing corrective surgery under heart lung machine

INHALED LEVOSIMENDAN VS INHALED MILRINONE IN CHILDREN WITH CONGENITAL HEART DISEASE WITH LEFT TO RIGHT SHUNT AND PULMONARY HYPERTENSION UNDERGOING SURGICAL CORRECTION UNDER CARDIO PULMONARY BYPASS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052544
Enrollment
41
Registered
2023-05-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Q219- Congenital malformation of cardiacseptum, unspecified Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Inhaled Milrinone: 50 mcg/kg drug as single dose nebulization through endotracheal tube in postoperative period after shifting to recovery Control Intervention1: Inhaled Levosimendan: 2

Sponsors

IPGMER and SSKM Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Congenital intracardiac left to right shunt complicated by Pulmonary artery hypertension (mean pulmonary artery pressure more than 20mm Hg as found during right heart catheterization) scheduled for surgical correction under Cardiopulmonary bypass

Exclusion criteria

Exclusion criteria: 1. refusal by guardians to give consent for the participation of their wards in the study 2. association with right-to-left shunts 3. history of previous cardiac surgery 4. heart failure (defined as failure of pumping function and manifested by dyspnea, tachypnea, chest wheezes, pulmonary edema, hepatomegaly, lower limb edema, and congested neck veins) preoperative inotropic support 5. hypersensitivity to Levosimendan and Milrinone 6. associated with Atrial Fibrillation 7. Re-exploration in ICU due to bleeding

Design outcomes

Primary

MeasureTime frame
Pulmonary Artery Systolic PressureTimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8 T0 after shifting to ICU pre inhalation T1 post inhalation T2 30 minutes of ICU stay T3 1 hour of ICU stay T4 2 hours of ICU stay T5 4 hours of ICU stay T6 6 hours of ICU stay T7 12 hours of ICU stay T8 24 hours of ICU stay

Secondary

MeasureTime frame
Central Venous PressureTimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8;Heart RateTimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8;Left Ventricular Ejection FractionTimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8;Mean Arterial PressureTimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8;Oxygen SaturationTimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8;Right ventricular fractional area changeTimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8;TR Jet VelocityTimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8;Tricuspid annular plane systolic excursionTimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8;Tricuspid STimepoint: Baseline, T0, T1, T2, T3, T4, T5, T6, T7, T8

Countries

India

Contacts

Public ContactSAURAV DAS

Institute of Post Graduate Medical Education and Research

soumidasanaesth79@gmail.com9433227409

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026